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Abstract   
 
 To date, the choice of therapy for an individual multiple myeloma patient has 
been based on clinical factors such as age and co-morbidities. The widespread 
evolution, validation and clinical utilization of molecular technologies, such as 
fluorescent in-situ hybridization and next generation sequencing has enabled the 
identification of a number of prognostic and predictive biomarkers for progression 
free, overall survival and treatment response. In this review we argue that in order to 
continue to improve myeloma patient outcomes incorporating such biomarkers into 
the routine diagnostic workup of patients will allow for the use of personalized, 
biologically based treatments. 
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Introduction 
Myeloma develops as the result of an evolutionary process during which a 
normal plasma cell moves through the pre-malignant state monoclonal gammopathy 
of uncertain significance (MGUS), to smoldering myeloma and myeloma that requires 
treatment.
1
 Advances in therapy over the last two decades have improved patient 
outcomes whilst the use of new technology has increased our understanding of the 
molecular drivers that underlie disease initiation and progression. Due to underlying 
molecular variation, the clinical disease course is very heterogeneous.
2
 Whilst some 
patients experience long remission periods, or functional cures, others relapse early or 
are refractory to therapy. In order to continue to improve outcomes, information 
regarding the molecular abnormalities driving these differences in outcomes needs to 
be incorporated into clinical care. These features may relate to mRNA, DNA or 
protein changes, but the aim is to identify aberrations that help inform the diagnosis, 
outcome or treatment relevant to a specific patient or subgroup of patients. Such 
molecular features or ‘biomarkers’ are defined by the NIH Biomarkers Definitions 
Working Group as ‘a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention’.3 
The purpose of using biomarker driven, personalized, treatment approaches is 
to maximize benefit and reduce toxicity. In order to achieve this goal, the biomarker 
must be measurable in a robust and reproducible manner. Advances in technology 
have helped the identification and validation of myeloma biomarkers relevant to 
treatment such as those that can predict outcome for patients based on differences in 
survival (prognostic biomarkers) or target treatment to subsets of patients based on 
specific molecular pathology (predictive biomarkers). Some biomarkers can clearly 
be both prognostic and predictive and approaches to target these are likely to have the 
greatest impact on outcomes.  
In this review we describe the current use of prognostic and predictive 
biomarkers in myeloma and speculate on advances that may enable further 
improvement in patient outcomes by employing these biomarkers to define 
personalized treatment strategies. 
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Advances in molecular profiling technologies enabling the identification of 
biomarkers 
The technologies enabling molecular profile analysis have evolved 
significantly over the last few decades contributing to an increased understanding of 
myeloma pathogenesis (Figure 1). Initial studies were performed using G-banding 
cytogenetics that identified translocations involving the immunoglobulin heavy chain 
(IgH) gene locus and hyperdiploidy as initiating events
4,5
. Translocations including 
t(4;14), t(6;14), t(11;14), t(14;16), and t(14;20) place oncogenes, MMSET/FGFR3, 
CCND3, CCND1, MAF and MAFB respectively, under the control of the IgH gene 
enhancer.
6,7
 The downstream effect of upregulation of these genes converges on the 
increased expression of cyclin D protein family members, ultimately driving G1/S 
checkpoint dysregulation.
8
 Hyperdiploidy, characterized by trisomies of odd 
numbered chromosomes also affects this checkpoint although the mechanism of its 
acquisition and downstream effect is less well understood. Subsequent studies have 
shown that secondary acquired lesions compound the cell cycle dysregulation, driving 
further proliferation and disease progression.
9
  
The use of fluorescence in-situ hybridization (FISH), gene expression 
profiling (GEP) and single nucleotide polymorphism (SNP) array technologies, have 
expanded the knowledge of the myeloma genome and enabled its further 
classification into subgroups.
8,10,11
 Cases cluster mainly based on the underlying 
structural genetic event (translocations and hyperdiploidy) with two classification 
systems surviving the test of time, the TC classification
8
 and University of Arkansas 
for Medical Sciences (UAMS)
10
 subgroups. 
In more recent years, the introduction of next generation sequencing (NGS) 
technologies has allowed the identification of single nucleotide variants as well as 
larger structural changes including translocations and copy number abnormalities 
more quickly and cheaply.
12-15
 Dozens of myeloma driver genes have been identified. 
The most common occur in the RAS and NF-kB families,
12,14,16
 with many mutations 
associated with the primary myeloma molecular subgroups suggesting the underlying 
background initiating event drives the acquisition of subsequent molecular 
abberations.
13
 A number of these new technologies are now CLIA certified and 
available for diagnostic use whilst additional techniques such as DNA methylation 
analysis remain confined to research laboratories. 
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Advances in prognostic biomarkers 
Prognostic biomarkers are used to identify the likelihood of disease relapse 
and/or predict overall survival. Classically they predict outcome irrespective of what 
therapy is given and enable more personalized outcome advice in the context of 
current treatment regimens. Several lesions have been identified as carrying an 
adverse outcome in myeloma. Some of these are clonal initiating lesions such as 
t(4;14), t(14;16) and t(14;20), whilst others are structural chromosomal changes or 
mutation events which tend to happen later in the evolutionary process. 
t(4;14) – incidence 10-15% at diagnosis 
The t(4;14) results in the histone methyltransferase, MMSET and tyrosine 
kinase, FGFR3 genes being placed downstream of IgH gene enhancers.
17
 The spiked 
expression of MMSET is likely responsible for the adverse outcome, as in the subset 
of patients with concomitant loss of FGFR3 expression the outcome is equally as 
poor.
17,18
 MMSET results in epigenetic reprogramming leading to a cascade of 
downstream effects including altered adhesion, enhanced growth and increased 
survival.
19
 This reprogramming also leads to genetic instability including gain(1q), 
del(12p), del(13q), del(22q) and BIRC2/3 homozygous deletion that may contribute to 
mediate the adverse outcomes.
20
 In comparison to other risk groups the t(4;14) is 
particularly heterogeneous in terms of outcome, potentially influenced by these 
additional lesions and/or co-occurrence of del(17p).
21
 
t(14;16)/t(14;20) – incidence 2-4% at diagnosis 
Similar genetic instability is seen in t(14;16) and t(14;20) cases that results in 
the upregulation of MAF and MAFB respectively and are associated with gain(1q) and 
del(17p). These subgroups are also associated with a mutational signature (a 
characteristic combination of mutation types) associated with the activity of the 
mRNA editing enzyme APOBEC and have an increased number of mutations.
16
 MAF 
and MAFb protein have been demonstrated to mediate resistance to proteasome 
inhibitors
22,23
, perhaps contributing to this subroup’s adverse outcome seen in most 
2,24,25
, though not all 
26
, studies. 
Del(17p) – incidence 8-10% (using threshold of 20% positive cells)  
Deletion of the short arm of chromosome 17 has been associated with adverse 
outcome, thought to be related to the loss of expression of the tumor suppressor 
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TP53.
27
 Whilst occasional studies suggest deletions in <20% of cells detected by 
FISH may have some clinical impact
28
, most studies utilize a cut off of >20% to 
demonstrate a significant effect.
29,30
 As the clone size increases the effect on outcome 
becomes more marked with some studies suggesting that clonal deletion in at least 
60% of cells is required.
31
 More recent data suggests that biallelic disruption either by 
two chromosomal deletions, by deletion in one and TP53 mutation in the other allele 
or biallelic mutation is what mediates the adverse outcome. 
29,32
 
Gain(1q) – incidence 30-35% at diagnosis 
Gain(1q) has been associated with adverse outcome although given the large 
number of genes situated on this chromosome, it is less clear which gene is 
responsible. Implicated genes at the most commonly gained locus (1q21) include 
BCL9, MCL1, CKS1B and ANP32E.
33-36
 This locus is susceptible to gain due 
instability of the pericentromeric chromatin.
37
 Other genes may also be important e.g. 
CD45 at 1q32 when larger regions of the chromosome are gained.
38
 There is an 
important distinction between gain, defined as one additional copy, and amplification, 
defined as >1 additional copy of 1q with amplified cases appearing to be associated 
with a more adverse outcome.
15,20,32
 
Other translocations/copy number abnormalities 
Del(1p) (incidence 10% at diagnosis) frequently co-occurs with gain(1q) and 
has been shown to be associated with an adverse outcome in patients undergoing 
autologous stem cell transplant. This effect is potentially mediated by loss of 
CDKN2C and FAF1 at 1p32 and/or FAM46C at 1p12 and/or RPL5 and EVI5 at 
1p22.
24,39,40
 
Myc aberrations (incidence 15-20% at diagnosis) are common and may be 
mediated by secondary translocations to the MYC locus at 8q22 or copy number 
change and are associated with adverse outcomes.
41,42
  
t(11;14) and hyperdiploidy are usually considered standard-risk. Some studies 
suggest that individual trisomies may be able to overcome some of the adverse impact 
of other lesions such as t(4;14) and del(17p), with trisomy 3 appearing to have the 
greatest impact.
43,44
 Another study looking at the impact of hyperdiploidy in this 
setting had conflicting findings.
45
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Mutations 
Mutations associated with adverse outcome that may function as prognostic 
biomarkers have also been identified and include those in CCND1 and DNA repair 
pathway genes (TP53, ATM, ATR and ZFHX4).
15,42
 Some mutations associated with a 
favorable outcome have also been identified eg IRF4 and EGR1. Mutational analysis 
of genomic instability can also predict for adverse outcomes with increases in 
genome-wide loss of heterozygosity associated with adverse outcomes.
46
 
RNA alterations 
 
Whilst DNA based assays are able to identify individual lesions and markers 
of global genomic instability, RNA and gene expression profiling (GEP) can be used 
to detect markers of increased proliferation and specific pathway expression 
changes.
47
 The GEP scores of 70 genes, GEP70 (MyPRS)
48
 or 92 genes, SKY92
49
, 
have prognostic capabilities better than using any single lesion discussed above. They 
identify high-risk outcomes in around 15% of patients at diagnosis. Their perceived 
limitations lie in the lack of widespread availability and computational analysis 
required to interpret the results. 
Novel fusion genes have also been identified in myeloma using RNA-seq data 
and some have been associated with adverse outcome, for example CSNK1G2 and 
CCND1 with shortened progression-free survival (PFS) and MMSET and BCL2L11 
with shortened overall survival (OS).
50
  
Other disease features 
 
Other features of disease may also indicate high-risk outcomes for patients and 
hence act as prognostic biomarkers. The presence of plasma cells with blastic 
morphology, renal failure, extramedullary disease
51
 and plasma cell leukemia at 
diagnosis all predict for worse outcomes. Circulating plasma cells, even at a lower 
level than meet the criteria for plasma cell leukemia, are also associated with adverse 
outcomes.
52,53
 Recent studies have shown that the number and size of focal lesions on 
PET-CT and MRI imaging also predict for a poor outcome independent of molecular 
features.
54
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Risk Stratification Systems – incorporating biomarkers 
With the advances in technology and the increase in size of the datasets 
examined, the information concerning the clinical impact of the presence of these 
molecular lesions has changed. This has resulted in a shift from using a single lesion 
to define high-risk disease to the use of two or three collaborating lesions. In addition, 
as so called ‘high-risk’ lesions can occur in up to 30-50% of patients, the need to 
identify a smaller group (e.g. <15%) of patients who truly perform badly regardless of 
therapy has become apparent. Such patients can be considered ‘ultra high-risk’ and 
have been identified in the following ways (Figure 2): 
 i. Presence of more than one adverse cytogenetic lesion 
 Translocations and copy number change associated with adverse outcome as 
describe above have been demonstrated to be cumulative such that the presence of 
more than one lesion predicts for a worse outcome than one lesion alone.
20,24
 In the 
MRC Myeloma IX study (Figure 2A) patients with more than one adverse lesion 
were termed ultra high-risk and comprised 15% of patients.  
 ii. R-ISS 
The Revised International Staging System (R-ISS) score built on this concept 
and incorporates B2M, albumin (from the previously used ISS) and LDH with 
structural lesions to more accurately predict risk. Risk is categorized into three 
groups, from low-risk R-ISS group I with ISS Stage I; no high-risk cytogenetic 
abnormality (CA) (del[17p] and/or t[4;14 and/or 14;16]) and normal LDH level; to 
high-risk R-ISS group III with ISS Stage III and high-risk CA or high LDH level 
(Figure 2B).
55
 Between 10-18% of patients are classified as R-ISS III.
55-58
  In this 
system each feature contributes equally to the risk group determination.  As more data 
becomes available and the understanding of how these features reflect myeloma 
biology increases, it can be envisaged that staging systems will be refined and 
features will be weighted.  
 iii Double hit myeloma 
Building on the scores defined above the Myeloma Genome Project 
incorporated NGS and structural abnormalities to better define risk (Figure 2C).
32
 
The study defined the highest risk patients as ‘double hit’ myeloma, that is patients 
with two ‘hits’ to the same gene, either loss of both alleles of TP53 (by mutation, 
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deletion or both) or with two extra copies of 1q resulting in amplification rather than a 
single gain. This group comprises 6-10% of patients and has a greater prognostic 
power than the R-ISS. A number of other groups have confirmed the importance of 
knowing both the copy number and TP53 mutation status, and this lesion along with 
amp(1q) now represents the most recent refinement in myeloma risk prediction. 
 
Interestingly, there remains a subset of patients carrying none of the molecular 
lesions discussed above who still relapse early.  Such patients can be considered high-
risk phenotypically as these patients in addition to having a short first PFS have a 
poor OS. Hence having become apparent, such patients may require therapy different 
to standard treatment at first relapse.
59
 Ongoing molecular studies may help to 
identify the currently unrecognized drivers in this early relapse group, as altering up-
front therapy remains likely to have the greatest benefit on long term survival. 
 
Prognostic biomarkers at different disease time points 
 The biomarkers described above were largely described in newly-diagnosed 
patient. Many adverse risk biomarkers become more frequent at later stages of the 
disease but still retain prognostic significance. Other biomarkers that can be 
incorporated later include response to therapy, especially when assessed by 
quantification of minimal residual disease (MRD) in the bone marrow (by next 
generation sequencing or next generation flow cytometry)
60-62
 or by imaging 
techniques.
63
 
 
Risk-adapted therapy for high-risk groups 
Aside from providing important prognostic information, the true benefit of 
identifying patients at high risk of early progression or death is to intervene and 
deliver different therapy to standard treatment. Such approaches are being 
investigated in several clinical trials. One of the challenges for these studies is that 
response rates generally do not differ between patients with high-risk and standard-
risk disease as the natural history of high-risk patients is to respond well but relapse 
early. As such depth of response may not have the same prognostic importance in 
high-risk groups. In patients defined as del(17p) or >=2 cytogenetic abnormalities, 
stringent complete response (sCR) and MRD negativity did not translate into a 
10 
 
superior PFS or OS.
64
 Early data suggests at deeper levels of MRD analysis this 
drawback may be overcome and confirmatory studies are awaited.
65
 
Trials concentrating on high-risk disease can be performed in two ways. In all-
comer trials the high-risk subgroup can be analyzed and reported separately and 
compared to non-high-risk patients, or trials can be specifically designed to optimize 
therapy for a prospectively recruited high-risk group (Figure 3A-B). The first 
approach provides reassurance on subgroup analysis that a given treatment shows as 
much benefit in the high-risk as standard-risk population but claims of efficacy in the 
smaller high-risk population will be limited by the statistical power and so large trials 
are required. The latter approach ensures studies are correctly powered to assess 
impact specifically in high-risk patients, however the definition of high-risk needs to 
be uniform and utilize reproducible biomarkers. 
Subgroup analysis of previously reported clinical trials has led to several 
approaches being suggested for high-risk patients.  This includes the observation that 
proteasome inhibitors overcome the some of adverse outcome associated with t(4;14) 
+/- del(17p).
66
  This initial data was based on a small subgroup analysis of the VISTA 
study. Subsequent studies, and a meta-analysis, confirmed that bortezomib-based 
induction results in improved outcomes versus non bortezomib-based induction but 
does not fully overcome the adverse prognostic impact of these lesions.
67,68
 A similar 
pattern is seen with lenalidomide maintenance post-autologous transplant (Jackson GJ 
et al, Lancet Oncology in press) suggesting novel agents can ameliorate but not 
abrogate adverse outcomes associated with high-risk disease. Studies in relapsed 
patients of the novel proteasome inhibitors carfilzomib and ixazomib also support this 
concept with a benefit over the control arm in high-risk patients but suboptimal 
outcomes compared to standard-risk patients.
69,70
  More recently in newly-diagnosed 
patients tandem autologous transplant, post-transplant consolidation and maintenance 
have all proved effective for high-risk patients compared to standard of care
71
 and 
may to some extent attenuate unfavorable outcomes, but no strategy to date is able to 
overcome the adverse effect of high-risk lesions completely. Prospective recruitment 
of high-risk patients to dedicated protocols is needed.  
High-risk patients are currently being recruited into a number of ongoing trials 
(Table 1). One example is the Total Therapy series of studies that initially started as 
risk-agnostic (TT1–TT3a/b) and later moved to high-risk studies (TT5, TT5b and 
TT7). The phase II TT5 trial
72
 recruited patients with GEP70 defined high-risk 
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disease and delivered dose dense chemotherapy, minimizing breaks between 
treatment phases by administering less intense therapy blocks aiming to prevent 
relapses that have been observed to occur during treatment breaks, for example during 
recovery from autologous transplant. Patients were compared to risk-matched patients 
in TT3 and no significant differences in survival were identified. However, the 
number of patients relapsing in the early treatment courses decreased with patients 
tending to relapse during the later maintenance phase. The latter iterations of the 
protocol (TT5b and TT7) have concentrated on this phase of treatment and are 
incorporating newer proteasome inhibitors and immune-based approaches. 
Other ongoing studies are examining intensification of induction, the use of 
autologous and allogeneic transplantation approaches and immunotherapy approaches 
such as CAR-T cells. The first approach is exemplified by the UK MUK9b trial 
(NCT03188172), the US 2015-12 trial (NCT03004287) and the German GMMG-
CONCEPT trial (NCT03104842) which all combine a CD38 antibody, proteasome 
inhibitor and lenalidomide as intensified upfront therapy along with prolonged 
courses of consolidation and maintenance. 
The major difference between each of these studies is the definition of high-
risk (e.g., GEP70, single or combinations of genetic lesions), which will make 
subsequent direct comparisons of PFS and OS challenging. However, there is little 
doubt that concentrating on this subgroup of myeloma will be a rewarding area for 
both patients and investigators. Given the long PFS and OS for standard-risk patients, 
trials designed for standard-risk require large numbers of patients and long follow up 
to demonstrate a statistical and meaningful clinical improvement of the intervention. 
The high-risk patient is an area of unmet clinical need and is also the ideal situation to 
demonstrate the clinical activity of a novel agent or novel approach and as such it is 
anticipated that other novel immunotherapy approaches such as CAR-NK cells, 
bispecific antibody therapy and antibody drug conjugates will move into first line 
studies for high-risk myeloma over the coming years. 
An alternative approach to altering upfront therapy is to utilize the prognostic 
biomarker of MRD post-induction to alter treatment at this time-point.  Studies 
addressing questions around intensification of therapy for MRD+ve patients or de-
escalating therapy for MRD-ve patients are in development. 
 
12 
 
Advances in predictive biomarkers 
In contrast to prognostic biomarkers, predictive biomarkers forecast the 
likelihood of a favorable or unfavorable outcome with a specific agent. From 
mutations alone it can be estimated that two thirds of patients have actionable lesions 
with agents currently available or in development.
15
 Other targetable lesions include 
primary translocation events and/or protein expression patterns. To date only a limited 
number, however, have been studied in clinical trials and these are discussed below. 
 
Targeted therapeutics using predictive biomarkers currently in clinical trials 
i. Venetoclax 
Venetoclax is an inhibitor of the anti-apoptotic protein BCL2. In-vitro data 
shows a higher sensitivity to venetoclax for cell lines and patient samples with a 
t(11;14). This is likely due to the higher BCL2 to MCL1 expression ratio that 
correlates with the presence of the translocation.
73,74
 Two early phase clinical studies 
have been published (Table 2). The first studied single agent venetoclax in multiply 
relapsed/refractory patients and demonstrated an overall response rate (ORR) of 40% 
amongst t(11;14) patients.
75
 The study also correlated BCL2:MCL1 and 
BCL2:BCL2L1 mRNA expression levels with responses and with t(11;14) status. The 
second study examined venetoclax in combination with bortezomib and 
dexamethasone. It demonstrated an ORR of 67% in all patients and 78% in t(11;14) 
patients. Similar to the single agent study, patients with higher BCL2 expression had 
deeper responses and longer PFS.
76
 The high efficacy of the combination in patients 
without the t(11;14) or high BCL2 expression was speculated to be due to bortezomib 
upregulating NOXA, a pro-apoptotic factor that neutralizes MCL1 resulting in an 
increased ratio of BCL2:MCL1 and sensitivity to venetoclax.
74
  
These findings suggest that moving forward venetoclax may not be limited to 
the t(11;14) subgroup and that when used in combination with a proteasome inhibitor, 
an assay measuring BCL2:MCL1 or BCL2:BCL2L1 mRNA expression ratios may be 
beneficial as a predictive biomarker. This biomarker driven strategy can be clearly 
seen with the trial combinations being examined in ongoing studies (Table 2), where 
those with proteasome inhibitor combinations are open to all comers whereas single 
agent studies are restricted to t(11;14) patients. 
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ii. RAS pathway inhibitors 
Sequencing studies have identified mutations in RAS in approximately 50% of 
patients (25% NRAS, 25% KRAS and 4% BRAF) leading to the evaluation of RAS 
pathway inhibitors. These include BRAF inhibitors (e.g., vemurafenib and 
dabrafenib), and MEK inhibitors (e.g., trametinib and cobimetinib). The published 
experience to date is mostly limited to case reports and case series (Table 3) and 
provides encouraging evidence of activity in relapsed/refractory patients (e.g. with 
responses seen in 16/40 patients with measurable disease
77
, although therapy was 
often in combination). Several prospective studies are now underway and should 
provide a more comprehensive analysis of efficacy (Table 3). 
iii. Therapies in development 
Further targets have been identified that may predict response to therapeutic 
agents although these are at earlier stages of development. Examples include 
IDH1/IDH2 mutations and IDH inhibitors
78,79
, loss of heterozygosity or ATM/ATR 
mutations and PARP inhibitors
46
 and FGFR3 mutations and FGFR3 inhibitors
80
. 
Several are being studied in large umbrella studies such as the Multiple Myeloma 
Research Foundation (MMRF) MyDRUG study and the Canadian “CAPTUR” study. 
These incorporate agents targeted to a large number of molecular drivers with a solid 
preclinical rationale, often repurposed from other diseases. Ongoing analysis is 
identifying further targets that can be incorporated into such studies. For example, 
fusion genes have been identified in myeloma and although rare (1%)
50,81
, the 
majority contain a kinase domain suggesting kinase inhibitors may have a potential 
role.   
Recent studies in solid tumor studies have shown that patients with a high 
mutation burden respond exceptionally well to PD1/PDL1 inhibitors.  Generally the 
mutation burden in myeloma is lower than solid tumors but a percentage of cases with 
a t(14;16) MAF translocation have an APOBEC signature and high mutational burden 
providing a biological rationale to explore checkpoint inhibitors in this small group.  
Limitations of targeted therapeutic approach 
 An important caveat of targeted agents used on the basis of predictive 
biomarkers is the presence of clonal heterogeneity as not all cells may contain the 
genetic lesion. Biopsies from distinct sites of disease within the same patient at one 
time point, or from the same site at different time points have been shown to be 
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molecularly diverse.
82
 These findings suggest that initiating events, present in 100% 
of clonal cells, may make good predictive biomarkers whereas secondary, usually 
subclonal, events would need to be in a high percentage of cells to be clinically 
useful. However, it could be hypothesized that where the targeted lesion is also of 
some prognostic importance, targeted therapy may still be clinically beneficial, for 
example by eliminating a high-risk clone and allowing a standard-risk clone to 
predominate may prove an effective therapeutic strategy. Using this logic, the best 
predictive lesions to target, but for which targeted agents unfortunately do not yet 
exist, are those that are present in a high proportion of clonal cells and are associated 
with adverse outcomes. For instance targeting MMSET, the oncogenic driver in 
t(4;14), fulfills both these criteria but has proved difficult for drug design to date. 
Other options include MAF targeted approaches and the identification and targeting 
of lesions associated with gain or amp(1q) and del(17p). 
Another limitation of mutation targeted therapy is the lack of integration of 
RNA and protein level data into the decision making process. Since drugs mostly act 
on proteins the effect of mutations at the protein level is important.  For example 
mutations in recurrent sites known to cause pathway activation may be acted upon 
clinically but variants of as yet unknown significance should be treated with caution. 
As more integrative molecular models become available this potential limitation may 
be overcome.  
Finally targeting individual lesions that occur in low frequencies in patient 
populations poses a logistical problem for clinical trial design and requires novel trial 
approaches. For instance for t(11;14) and RAS pathway mutations, present in 15 and 
50% of patients respectively, it is still possible to run lesion specific trials. In contrast, 
attempting to target lesions such as IDH mutations, present in <2% of patients, will 
require multi-center and potentially multi-disease collaborations. Such concepts are 
employed in umbrella studies (Figure 3C) or Basket studies (Figure 3D) where 
patients with different tumors are enrolled in the same protocol based on a molecular 
lesion identified. In addition, given the scarcity of some lesions in specific disease 
there is an argument that more single patient experiences also warrant publication. 
Conclusions 
The improvement in survival for myeloma patients over the last decade has 
mainly benefited low-risk patients and now that PFS for this group of patients is in 
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excess of 8 years a new approach to improving outcomes is required.  Current 
approaches to personalize myeloma therapy take into account age and co-morbidities 
but rarely consider molecular information.  However, as the information concerning 
genetic analysis has become stronger, it can be postulated that one way to quickly 
improve outcomes further would be to incorporate such information into clinical 
algorithms. We have described two possible approaches by which this might be 
achieved. The first targets a cohort of patients with high-risk markers using intensified 
therapeutic approaches agnostic to molecular lesions.  Such approaches include 
combinations of quadruplet or even quintuplet regimens and/or novel immunotherapy 
approaches such as bi-specific antibodies, antibody drug conjugates and CAR-T cells. 
This approach has the benefit of targeting patients with the worst outcomes and 
highest unmet clinical need.  The challenge, however, is the lack of understanding 
about whether this is best achieved by incorporating an ever increasing numbers of 
additional agents, novel immunotherapy agents or whether the focus should be on 
designing more optimal treatment delivery approaches, such as different schedules 
and sequencing approaches using currently available agents. 
The alternative strategy is to aim to use molecularly targeted agents that target 
lesions specific to an individual patient’s disease and therefore have a higher 
likelihood of efficacy whilst avoiding unnecessary toxicity. The knowledge of the 
molecular basis of myeloma is ever expanding and so we can use this to define 
rationale drug targets as well as to utilize drugs already available for known targets. 
With respect to such predictive biomarkers utilizing therapies targeted to either 
initiating lesions or lesions with a high cancer clonal fraction seem most likely to be 
effective. In addition it seems likely that molecularly targeted agents will not be used 
alone, instead, these agents will be combined in specific subsets of disease with other 
agents that target more general plasma cell biological functions such as proteasome 
inhibitors, immunomodulatory drugs and monoclonal antibodies.  
In closing, it is important to note that work to date concerning prognostic and 
predictive biomarkers has concentrated on genetic lesions within the plasma cell. 
Advances in protein technologies are occurring rapidly with the advent of tabletop 
analyzers,
11
 mass spectrometry,
12
 next generation flow cytometry, mass cytometry 
(CyTOF) and whole proteome analysis.  These technologies will allow the study the 
myeloma proteome as well as components of the microenvironment and immune 
environment. With the increasing use of immune therapies it seems likely that 
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biomarkers related to these areas will be identified and will need to be incorporated 
into current models and treatment decisions. 
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Figures: 
 
 
 
 
 
 
 
Figure 1 - The Evolution of Molecular Analysis Techniques in Myeloma. 
Images from left to right show G-band karyotyping, fluorescence in situ hybridization 
(FISH), gene expression profiling (GEP) data, single nucleotide polymorphism (SNP) 
array data, next generation sequencing (NGS) data.   
Image attributions:  
Evolution outline CC-0.  
Karyotype CC-BY: Panagopoulos I. et al. (2018) RUNX1-PDCD6 fusion resulting from a novel t(5;21)(p15;q22) 
chromosome translocation in myelodysplastic syndrome secondary to chronic lymphocytic leukemia. PLOS ONE 
13(4): e0196181.  
FISH CC-BY: Fernando RC. et al. (2015) Multiple myeloma cell lines and primary tumors proteoma: protein 
biosynthesis and immune system as potential therapeutic targets. Genes & Cancer 6:11-12. 
GEP CC-BY: André T. et al. (2013) Evidences of Early Senescence in Multiple Myeloma Bone Marrow 
Mesenchymal Stromal Cells. PLOS ONE 8(3): e59756.  
SNP array and NGS CC-BY: Bolli N. et al. (2018) Genomic patterns of progression in smoldering multiple 
myeloma. Nature Comms (9) 3363. 
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Figure 2 – Risk Stratification Systems and Outcome 
Progression-free survival as defined by the different risk stratification systems. 
A) Ultra high-risk defined by the presence of more than one adverse lesion [t(4;14), 
t(14;16), t(14;20), del(17p) and gain(1q)] in the analysis of 869 cases from the MRC 
Myeloma IX trial, published 2011. 
B) Ultra high-risk defined by the R-ISS [low-risk R-ISS group I with ISS Stage I; no 
high-risk cytogenetic abnormality (CA) (del[17p] and/or t[4;14 and/or 14;16]) and 
normal LDH level; to high-risk R-ISS group III with ISS Stage III and high-risk CA 
or high LDH level] in a pooled study of 4,445 patients with NDMM from 11 clinical 
studies. Published 2016 
C) Ultra high-risk defined as “double-hit” myeloma [either loss of both alleles of 
TP53 (by mutation, deletion or both) or with two extra copies of 1q resulting in 
amplification rather than a single gain] by incorporating next generation sequencing 
data in the Myeloma Genome Project analysis of 784 patients, published 2018.   
Image attributions: 
A) Permission for re-use under Springer Nature Author Reuse Guidelines - To reuse figures or tables created by 
the Author and contained in the Contribution in oral presentations and other works created by them. Original 
figure published in Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-
segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 
2012;26:349-55. FED is an author of both manuscripts. 
B) Permission for re-use will be sought. 
C) Image licensed for re-use under CC-BY. Original publication in Walker BA, Mavrommatis K, Wardell CP, et 
al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 2018.     
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Figure 3 – Clinical Trial Design Strategies for Personalized Treatment in 
Myeloma 
A) Current standard approach with all patients recruited and treated as part of a 
clinical trial with subsequent subgroup analysis that may, or may not, be adequately 
powered to examine the effect of the novel strategy in high-risk patients. 
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B) Trial design for high-risk patients which are identified upfront and entered into 
dedicated protocols.  These may be phase II or III randomized studies (as shown) or 
earlier phase single arm studies. 
C) Umbrella trial design with patient molecular lesions identified up front and entered 
into an arm examining a therapy appropriate to that lesion. 
D) Basket trial design with patients with different cancers but with a shared molecular 
lesion entered into a study with an agent targeted to that lesion.   
Image attributions: 
Figure of man and woman downloaded from https://www.aiga.org/symbol-signs  - free to use. 
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Tables: 
Table 1 – Clinical Studies Specifically targeting high-risk disease in newly diagnosed myeloma patients 
As per clinical trials.gov search for “high-risk myeloma” and including studies where the high-risk definition was included. 
 
 NCT number Status Location Ph. Treatment schema Definition of high-risk used in the study 
Reported studies 
TT5 NCT00869232 Active, not 
recruiting 
US 2   GEP70 defined high-risk gene expression profiling  
Ongoing studies 
Novel intensified combinations 
TT5b NCT02128230 Recruiting US 2   GEP70 defined high-risk gene expression profiling 
MUK9b OPTIMUM Treatment 
Protocol 
NCT03188172 Recruiting UK 2 Dara-CVRD  Two of: (4;14), t(14;16), t(14;20), del(17p), gain(1q), del(1p)  
 SKY92 defined high-risk gene expression profiling  
 Plasma cell leukemia 
2015-12: A Study Exploring the Use of 
Early and Late 
Consolidation/Maintenance Therapy 
NCT03004287 Recruiting US 2 Dara, carfilzomib or bortezomib, 
thalidomide, lenalidomide, 
dexamethasone, cisplatin, 
adriamycin, cyclophosphamide, 
etoposide, lenalidomide and 
dexamethasone. 
 Myeloma Prognostic Risk Signature (MyPRS) risk score ≥ 50.4 
 Lactate Dehydrogenase (LDH) ≥ 360 U/L  
 Plasma cell leukemia. 
Evaluation Induction, Consolidation 
and Maintenance Treatment With 
Isatuximab , Carfilzomib, Lenalidomide 
and Dexamethasone 
NCT03104842 Recruiting DE 2 Isatuximab-KRDx6 
Isa-KRDx4 
Isa-KR maintenance 
 
TE and TNE 
 Presence of one or more of the following cytogenetic abnormalities 
(determined by FISH): 
o Del(17p) in ≥ 10% of purified cells 
o t(4;14) 
o > 3 copies +1q21 
 ISS Stage II or III (all patients) 
S1211 Bortezomib, Dexamethasone, 
and Lenalidomide With or Without 
Elotuzumab in Treating Patients With 
Newly Diagnosed High-Risk Multiple 
Myeloma 
NCT01668719 Recruiting US 
SWOG 
1/2 Elo-VRD vs VRD  GEP70 or SKY92 defined high-risk gene expression profiling  
 Translocation (14;16), and/or translocation (14;20), and/or deletion 
(17p) by FISH or cytogenetics  
 Plasma cell leukemia  
 Lactate dehydrogenase (LDH) >= 2 x institutional upper limit of 
normal (IULN)  
 1q21 amplification by FISH analysis  
An Intensive Program With Quadruplet 
Induction and Consolidation Plus 
Tandem Autologous Stem Cell 
Transplantation in Newly Diagnosed 
High Risk Multiple Myeloma Patients: 
a Phase II Study of the Intergroupe 
 NCT03606577 Not yet 
recruiting 
FR 2 Dara-KRd induction and 
consolidation and tandem ASCT, 
Dara-R maintenance 
 FISH analysis: del(17p), or t(14;16) or t(4;14). The FISH-positivity 
cut-off value for defining the presence of del(17p) in this study is 50% 
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Francophone du Myélome "IFM 2018-
04" (IFM 2018-04) 
A Single Arm Study of Carfilzomib in 
Transplant Eligible High Risk Multiple 
Myeloma 
NCT02217163 Active, not 
recruiting 
SG 2 Carfilzomib, cyclophosphamide and 
dexamethasone for up to 8 cycles 
prior to ASCT 
 International Staging System (ISS) III 
 del(17p), t(4;14), t(14;16), t(14;20), gain(1q) 
 
Auto/Allo approaches 
Autologous or Syngeneic Stem Cell 
Transplant Followed by Donor Stem 
Cell Transplant and Bortezomib in 
Treating Patients With Newly 
Diagnosed High-Risk, Relapsed, or 
Refractory Multiple Myeloma 
NCT00793572 Active, not 
recruiting 
US 2 
 
 
 
Auto/allo after VAD induction.  
Maintenance velcade. 
 Any abnormal karyotype by metaphase analysis except for isolated 
t(11,14) and constitutional cytogenetic abnormality 
 FISH detection of t(4;14), t(14;16) or deletion 17p 
 Beta2-microglobulin > 5.5 mg/L 
 Cytogenetic hypodiploidy 
 Plasmablastic morphology (>= 2%) 
Allogeneic Hematopoietic Stem Cell 
Transplantation With Ixazomib for 
High Risk Multiple Myeloma (BMT 
CTN 1302) 
NCT02440464 Recruiting US 2 
 
Ixazomib vs placebo post allogeneic 
transplant 
 
 del(13), gain(1q), del(1p), t(4;14), t(14;16), t(14;20), del(17p) or high-
risk criteria based on commercially available gene expression profiling 
(GEP) ; and elevated beta-2 microglobulin (≥ 5.5 mg/L at diagnosis). 
 Plasma cell leukaemia 
 Relapsed within 18 months of 1st line therapy 
ECT-001 (UM171) Expanded Cord 
Blood Transplant to Treat High-risk 
Multiple Myeloma 
NCT03441958 Recruiting CA 1/2 ECT-001 (UM171) expanded cord 
blood allogeneic transplant 
 t(4;14), t(14;16), t(14;20), del(17p13), chromosome 1 abnormalities 
with ISS II or III 
 Revised-ISS 3 
 Plasma cell leukemia 
 Refractory to first line triplet bortezomib-based induction treatment.  
 ≥ 2 cytogenetics abnormalities as defined above regardless of ISS 
stage 
Nonmyeloablative Allogeneic Stem 
Cell Transplant Followed by 
Bortezomib in High-risk Multiple 
Myeloma Patients 
NCT02308280 Recruiting CA 2 Non myeloablative allogeneic 
transplantation followed by 
Bortezomib for 1 year after a 
Bortezomib-based induction and 
autologous stem cell 
transplantation. 
Bortezomib: 1,3 mg/m2 
subcutaneously every 2 weeks for 
26 injections. 
 International Staging System (ISS) III 
 del(17p13), t(4;14) with ISS II or III, t(14;16), t(14;20) and 
chromosome 1 abnormalities by FISH 
 Plasma cell leukemia 
 Patients ≤ 50 years, regardless of cytogenetics or ISS stage 
Immunotherapy approaches 
Up-front CART-BCMA With or 
Without huCART19 in High-risk 
Multiple Myeloma 
NCT03549442 Recruiting US 1   Beta-2-microglobulin ≥ 5.5 mg/L and LDH greater than upper limit of 
normal.  
 High-risk FISH features: del(17p), t(14;16), t(14;20), t(4;14) in 
conjunction with Beta- 2-microglobulin ≥ 5.5 mg/L (i.e., revised ISS 
stage 3).  
 Metaphase karyotype with >3 structural abnormalities except 
hyperdiploidy 
 Plasma cell leukemia (>20% plasma cells in peripheral blood) 
 Failure to achieve partial response or better to initial therapy with an 
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"imid/PI" combination (thalidomide, lenalidomide, or pomalidomide 
in combination with bortezomib, ixazomib, or carfilzomib). 
 Early progression on first-line therapy, defined as progression 
CART-19 Post-ASCT for Multiple 
Myeloma 
NCT02794246 Active, not 
recruiting 
US 2 CD19 CAR administered after 
ASCT 
 Any of the following high-risk cytogenetic features, documented by 
FISH or metaphase karyotyping: del(17p), t(4;14), t(14;16), t(14;20). 
 Standard-risk cytogenetics but elevated LDH and beta-2-microglobulin 
> 5.5 mg/L (i.e., R-ISS stage III). 
Study of T Cells Targeting 
CD19/BCMA (CART-19/BCMA) for 
High Risk Multiple Myeloma Followed 
With Auto-HSCT 
NCT03455972 Recruiting CN 1 Anti-CD19/BCMA CAR 
administed after ASCT 
 not achieved VGPR before stem cell mobilization 
 R-ISS III stage  
 extramedullary disease 
 del(17p), t(4;14), t(14;16) 
Pembrolizumab + Lenalidomide Post 
Autologous Stem Cell Transplant 
(ASCT) in High-risk Multiple Myeloma 
(MM) 
NCT02906332 
 
 
 
Active, not 
recruiting 
US 2 Pembrolizumab and lenalidomide 
maintenance post-ASCT 
 International Staging System (ISS) stage 3  
 Deletion 13q by cytogenetics, and/or 
 1q amplification, 1p deletion, p53 deletions (17p deletions), t(4;14), 
t(14;16), t(14;20), hypodiploidy,  
 High-risk gene expression profile (GEP) scores 
2015-10: Expanded Natural Killer Cells 
and Elotuzumab for High-Risk 
Myeloma Post- Autologous Stem Cell 
Transplant (ASCT) 
NCT03003728 Not yet 
recruiting 
US 2 Elotuzumab and expanded natural 
killer cells post ASCT 
 Gene Expression Profiling (GEP) 70 risk score of ≥ 0.66  
 GEP 80 gene score of ≥ 2.48  
 metaphase cytogenetic abnormalities  
 lactate dehydrogenase (LDH) ≥ 360 U/L 
Completed, as yet unreported studies 
Bortezomib, Doxorubicin 
Hydrochloride Liposome, and 
Dexamethasone Followed by 
Thalidomide and Dexamethasone With 
or Without Bortezomib in Treating 
Patients With Multiple Myeloma 
NCT00458705 Completed US 2 Bortezomib, liposomal doxorubicin 
and dexamethasone x 3 
Thal/dex x 2 
 High-risk disease, defined as symptomatic International Staging 
System (ISS) stage 2 or 3 
 Soft-tissue plasmacytoma 
 Extension of a plasmacytoma into soft tissues 
 Primary resistant myeloma, defined as unchanged or progressive diase 
despite two courses of standard treatment 
Combination Bortezomib-containing 
Regimens in Newly Diagnosed Patients 
With t(4; 14) Positive Multiple 
Myeloma 
NCT00570180 Completed CA 2 Vel, dex, liposomal dox x 4 
ASCT 
Cyclo, vel, pred x 8 
+ dex maintenance 
 t(4;14) 
Celgene High Risk Multiple Myeloma 
(MM) Revlimid Induction and 
Maintenance Therapy 
NCT00691704 Completed US 2 Induction: 
Rd x4  
Sequential maintenance: 
- Velcade 
- MP 
- Len 
 Deletion of chromosome 13 by cytogenetics 
 Del(17p) by FISH or metaphase analysis 
 FISH detection of t(4;14), t(14;16), t(8;14), or t(14;20)  
 hypodiploidy detected by FISH or metaphase analysis 
 any complex cytogenetic abnormality detected by cytogenetics , with 
the exception of hyperdiploidy 
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Stem Cell Transplantation To Treat 
High Risk Multiple Myeloma With 
Reduced Toxicity Myeloablative 
Conditioning Regimen 
NCT00615589 Terminated, 
low accrual 
US 2 Fludarabine/busulfan conditioned 
MUD allo 
 Stage II/III, any of: t(4; 14), t(14; 16),(14:20) by FISH; 17p- by 
conventional cytogenetics or FISH; ∆13 by conventional cytogenetics; 
Hypodiploidy by conventional cytogenetics. 
 Relapsed or persistent disease after ASCT. 
 Persistent disease regardless of previous therapies. 
 Plasma cell leukemia, regardless of previous therapies. 
Vismodegib After Stem Cell Transplant 
in Treating Patients With High-Risk 
First Remission or Relapsed Multiple 
Myeloma 
NCT01330173 Completed US 1 Vismodegib (hedgehog inhibitor) 
after ASCT 
 
 Del(13), t(4;14), t(14;16) or del(17p) 
 B2-M > 5.5 g/dL 
 immunoglobulin A [IgA] phenotype 
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Table 2 – Clinical Studies of Venetoclax 
As per clinical trials.gov and Pubmed searches for “myeloma” and “venetoclax”. 
 
Published studies 
Phase Year published Patient population Combination Administration 
 
No.  No. t(11;14) ORR in all ORR in 
t(11;14) 
1 201775 Relapsed/refractory 
61% bortezomib and 
lenalidomide double refractory 
Venetoclax  Intrapatient escalation to max 300, 600, 900 and 
1200mg cohorts, expansion of 1200mg cohort.  
Dexamethasone could be added at progression on 
venetoclax. 
66 30 21% 40% 
1b 201776 Relapsed/refractory 
39% bortezomib refractory 
53% lenalidomide refractory 
 
Venetoclax, bortezomib 
and dexamethasone 
Intrapatient escalation to max 100, 200, 300, 400, 500, 
600, 800, 1000 and 1200mg cohort, expansion of 
800mg cohort.  In combination with bortezomib and 
dexamethasone 
66 9 67% 78% 
Ongoing studies  
 
Phase Location Patient population Combination/Administration NCT Estimated 
completion 
1b US, Australia, 
France 
Relapsed after at least 1 prior 
line of therapy 
Venetoclax, bortezomib and dexamethasone NCT01794507 2018 
1/2 US, Australia, 
Canada, 
Europe 
Part 1: t(11;14) 
relapsed/refractory 
 
Part 2: relapsed/refractory 
Dose escalation of venetoclax with fixed doses of daratumumab and dexamethasone (plus 
bortezomib for part 2) 
NCT03314181 2023 
1/2 US and Europe Relapsed after at least one prior 
line of therapy, 
t(11;14) 
Venetoclax +/- dexamethasone NCT01794520 2021 
1b/2 Europe Relapsed/refractory 
3-5 prior lines of therapy 
Arm A: cobimetinib 
Arm B: cobimetinib plus venetoclax 
Arm C: cobimetinib, venetoclax plus atezolizumab 
NCT03312530 2020 
2 US 
 
Relapsed/refractory 1-3 prior 
lines of therapy 
Venetoclax, carfilzomib and dexamethasone NCT02899052 
 
2020 
2 US, Europe Relapsed after at least one prior 
line of therapy, cohorts for 
t(11;14) positive and negative 
Venetoclax, pomalidomide and dexamethasone NCT03567616 2020 
3 World-wide Considered sensitive or naïve to 
proteasome inhibitors and 
received 1 to 3 prior lines of 
therapy 
Venetoclax/placebo plus bortezomib and dexmathasone NCT02755597 2020 
3 World-wide t(11;14) 
Relapsed/ refractory 
Venetoclax and dexamethasone vs pomalidomide and dexamethasone NCT03539744 2022 
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Table 3 - Clinical Studies of RAS Pathway Targeted Therapies  
As per clinical trials.gov and Pubmed search for “myeloma” and the following terms “vemurafenib”, “dabrafenib”, “trametinib”, “cobimetinib”, “RAS”, “BRAF”, “MEK”. 
 
Retrospective cohorts and case reports 
Type Year 
published 
Patient population Combination/Administration 
 
Number of patients Overall response rate 
Retrospective 201677 Oncogenic mutations of NRAS, KRAS or BRAF or GEP 
pathway activation in relapsed/refractory patients 
Trametinib as single agent or in 
combination with other agents 
58, 40 with measurable disease at time 
of commencing trametinib 
16/40 (40%) 
Case report 201783 Relapsed/refractory patient with extramedullary disease and 
BRAF V600E mutation 
Vemurafenib and cobimetinib 1 Patient responded 
Case report 201484 Relapsed/refractory patient with extramedullary disease and 
BRAF V600E mutation 
Vemurafenib 1 Patient progressed through 
treatment 
Case report 201485 Relapsed/refractory patients with BRAF V600E mutations  Vemurafenib 2 Both patients responded 
Case report 201386 Relapsed/refractory patient with extramedullary disease and 
BRAF V600E mutation 
Vemurafenib 1 Patient responded 
Ongoing studies  
Phase Location Patient population Combination/Administration NCT Estimated 
completion 
1 UK Relapsed/refractory 
BRAF, NRAS or KRAS mutated 
RO5126766 twice weekly or Mon/Wed/Fri dosing schedule NCT02407509 2016 
(but ongoing) 
1 Boston, US Relapsed/refractory 
BRAF, NRAS or KRAS mutated 
Cohort 1 BRAF V600 mutated: Dabrafenib 
Cohort 2 BRAF mutated or BRAF plus KRAS/NRAS mutated: trametinib 
Cohort 3: KRAS or NRAS mutated: trametinib 
NCT03091257 2021 
2 Canada Relapsed/refractory 
BRAF, NRAS or KRAS mutated 
Trametinib initially with AKT inhibitor GSK2141795 added at progression 
Cohorts of biomarker positive and negative patients 
NCT01989598 2018 
2 Germany Relapsed/refractory 
BRAF V600E/K mutated 
Encorafenib and binimetinib combination NCT02834364 2021 
1b/2 Europe Relapsed/refractory 
3-5 prior lines of therapy 
Arm A: cobimetinib 
Arm B: cobimetinib plus venetoclax 
Arm C: cobimetinib, venetoclax plus atezolizumab 
NCT03312530 2020 
Umbrella studies 
2 US MATCH study: 
Multiple diseases and multiple treatments 
Guided by molecular characterization including BRAF, RAS, PIKC3A mutations, 
CCND1, CDK4, CDK6 amplification 
NCT02465060 2022 
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US TAPUR study: 
Multiple diseases and multiple treatments 
Guided by genomic variant identification including BRAF, KRAS, NRAS NCT02693535 2019 
2 Canada CAPTUR study: 
Multiple diseases and multiple treatments 
Guided by genomic variant identification including BRAF NCT03297606 2021 
 
